LMR Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

LMR Partners’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-17,469	Closed	-$45K	–	1392
2022 Q3	$45K	Hold	17,469	–	–	﹤0.01%	1107
2022 Q2	$34K	Buy	+17,469	New	+$38.1K	﹤0.01%	1192

Other funds holding PRTK

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

LMR Partners's PRTK Position: Q4 2022 in Review

LMR Partners sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2022, closing a stake of 17,469 shares — an estimated $45K sold.

LMR Partners first reported a position in PRTK in Q2 2022 and held it in 2 quarters. The position peaked at $45K in Q3 2022. 76 funds tracked by Wall St. Rank hold PRTK as of Q4 2022.

LMR Partners reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
LMR Partners sold 17,469 Paratek Pharmaceuticals, Inc. shares in Q4 2022, an estimated $45K.
LMR Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2022 and held it in 2 quarters.
LMR Partners's Paratek Pharmaceuticals, Inc. position peaked at $45K in Q3 2022.
76 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.